Natera

The technology Natera has developed is like finding a single blade of grass in 100,000 soccer fields—Finding a single DNA molecule in a regular blood draw from the arm that carries a cancer mutation.

Catch diseases early, treat them early, and lower healthcare costs—That's what integrated risk models are all about. DNA Today

The first patients have begun enrolling in the HEROES clinical trial, which is evaluating the use of Natera’s Signatera MRD test for de-escalation or discontinuation of therapy in metastatic HER2+ breast cancer. Safely discontinuing treatment has been a long-lasting dilemma in this type of breast cancer. With Signatera, we hope oncologists can identify the patients without detectable disease who may be able to avoid additional therapy that can be costly and potentially harmful to their care. Learn more: https://ow.ly/zNns50VeVGb

Genome sequencing costs under 2% of the annual per capita health budget—small cost, massive savings. DNA Today Kira Dineen, MS, LCGC, CG(ASCP)CM https://lnkd.in/dEbfQX7J

ACMG 2025 is around the corner! Join us on March 19 for our session: Precision Medicine across Oncology, Renal Genetics, and Reproductive Health. Genomic testing has traditionally been used for diagnosis. In this session, attendees will learn how results can be used to identify patients who would benefit from further testing and to inform treatment options. Join Natera to learn how genetic testing can enable a personalized approach with the potential to improve outcomes. We will also explore: ??How data from molecular residual disease testing can enhance awareness of hereditary cancer testing ??The interaction between the genetic causes of kidney disease and targeted therapies ??How expansion of prenatal screening improves outcomes through early diagnosis and perinatal treatment options Featuring: John Williams III, MD Director of Reproductive Genetics and Professor of Obstetrics and Gynecology at Cedars-Sinai Medical Center and the David Geffen School of Medicine at UCLA A. Katya Brossart, MS, CGC Manager of Genetics Education & Engagement Organ Health, Natera Eileen Hoffman, MS, CGC Medical Science Liaison, Natera Oncology Moderated by: Sheetal Parmar, MS, CGC SVP Medical Affairs, Natera Women's Health ACMG - American College of Medical Genetics and Genomics Natera Oncology Natera Organ Health Natera Women's Health #Natera #ACMG #ACMGMtg25

Exciting news! Natera CEO Steve Chapman has been appointed to the Board of Directors of the American Clinical Laboratory Association (ACLA). ?? ACLA advocates for policies that expand access to high-quality clinical laboratory services, improve patient outcomes, and advance the next generation of personalized care. https://ow.ly/Gu3Q50V9rGG

With today’s news that Medicare will cover Signatera for stage I-III non-small cell lung cancer in surveillance, Signatera is now more accessible to patients living with lung cancer – the most lethal and one of the most common forms of cancer in the United States. Signatera test performance and utility in the surveillance setting for stage I-III NSCLC was validated in three independent peer-reviewed studies to support this coverage determination. The body of evidence continues to grow demonstrating Signatera’s value across a broad range of cancer indications and settings. Read more in our latest press release. https://ow.ly/44Jf50V65LQ

Such amazing energy at the Natera Global Sales Meeting a few weeks ago. What a wonderful team with whom to share the message that we’re just getting started. Thank you.

Congratulations to Chitra Kotwaliwale, Ph.D., SVP of Clinical & Commercial Operations at Natera, for being named one of the Top 50 Women Leaders in Healthcare Technology by The Healthcare Technology Report! This recognition is a testament to her enduring impact and leadership. ?? https://ow.ly/T3Fy50UXH5i

We’re pleased to share that the National Comprehensive Cancer Network? (NCCN?) strengthened its guidance on circulating tumor DNA (ctDNA) testing in colon cancer, rectal cancer, and merkel cell carcinoma (MCC). These are significant milestones for MRD testing and Signatera, as we work to improve the management of patients with cancer. For colon and rectal cancer, NCCN now includes ctDNA as a high-risk factor for recurrence in the adjuvant setting, recognizing its prognostic value. This represents an important step forward as the first time the guidelines have formally recognized the value of ctDNA as a prognostic biomarker. In MCC, the guideline now includes a positive recommendation for ctDNA monitoring in surveillance and cites Signatera data published in 2024 in the Journal of Clinical Oncology. We are hopeful these are the first of many major updates to NCCN guidelines re: ctDNA for MRD assessment, underscoring the important role Signatera has in helping patients with cancer. https://ow.ly/Q83850UX9bZ #Signatera #Natera #ctDNA #Merkel